Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients
| Autor: | J H Laragh, C L Christian, H Maricq, G Botstein, D B Case, H H Whitman rd, E C Leroy |
|---|---|
| Rok vydání: | 1982 |
| Předmět: |
Adult
medicine.medical_specialty Captopril Immunology Encephalopathy Scleroderma Renal Crisis Administration Oral Renal function Angiotensin-Converting Enzyme Inhibitors urologic and male genital diseases Scleroderma Hypertension Malignant Rheumatology Internal medicine Renin Humans Immunology and Allergy Medicine Pharmacology (medical) skin and connective tissue diseases Aged Scleroderma Systemic integumentary system biology business.industry Angiotensin-converting enzyme Middle Aged medicine.disease Blockade Blood pressure Creatinine Hypertension biology.protein Cardiology business medicine.drug |
| Zdroj: | Arthritis & Rheumatism. 25:241-248 |
| ISSN: | 1529-0131 0004-3591 |
| DOI: | 10.1002/art.1780250301 |
| Popis: | Twelve scleroderma patients with hypertension, seven of whom had malignant hypertension and renal failure of scleroderma renal crisis, were treated with captopril. The first dose lowered mean pressure in all patients by 21.3 mmHg; in 6 patients it relieved encephalopathy. Blood pressure was controlled in all patients. Two of 7 patients with scleroderma renal crisis had improvement in renal function; the 5 patients who did not have malignant hypertension improved or stabilized. Despite good pressure control, however, renal failure developed in 5 patients with scleroderma renal crisis. The data indicated that captopril is effective antihypertensive therapy in scleroderma and, when given early, may prevent renal failure and death. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text